{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:20:26Z","timestamp":1779931226253,"version":"3.53.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11606-011-1633-9","type":"journal-article","created":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T20:48:02Z","timestamp":1296506882000},"page":"603-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Different Black Box Warning Labeling for Same-Class Drugs"],"prefix":"10.1007","volume":"26","author":[{"given":"Orestis A.","family":"Panagiotou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina G.","family":"Contopoulos-Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis N.","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia E.","family":"Ntzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P. A.","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"1633_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200\u20135.","journal-title":"JAMA"},{"key":"1633_CR2","doi-asserted-by":"publisher","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","volume":"4","author":"EC Davies","year":"2009","unstructured":"Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009;4:e4439.","journal-title":"PLoS ONE"},{"key":"1633_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2125.2007.03064.x","volume":"65","author":"K Wester","year":"2008","unstructured":"Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008;65:573\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1633_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11606-009-1141-3","volume":"25","author":"BL Hug","year":"2010","unstructured":"Hug BL, Witkowski DJ, Sox CM, et al. Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention. J Gen Intern Med 2010;25:31\u20138.","journal-title":"J Gen Intern Med"},{"key":"1633_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/archinternmed.2010.91","volume":"170","author":"CM Cheng","year":"2010","unstructured":"Cheng CM, Guglielmo BJ, Maselli J, Auerbach AD. Coverage of FDA medication boxed warnings in commonly used drug information resources. Arch Intern Med 2010;170:831\u20133.","journal-title":"Arch Intern Med"},{"key":"1633_CR6","first-page":"259","volume":"81","author":"NS Marks","year":"2010","unstructured":"Marks NS, Weiss K. Boxed warnings and other FDA communication tools. Am Fam Physician 2010;81:259.","journal-title":"Am Fam Physician"},{"key":"1633_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.gerinurse.2008.09.005","volume":"29","author":"BJ Zarowitz","year":"2008","unstructured":"Zarowitz BJ. Black box warnings\u2014implications in practice. Geriatr Nurs 2008;29:402\u20139.","journal-title":"Geriatr Nurs"},{"key":"1633_CR8","first-page":"e103","volume":"15","author":"JR Ricci","year":"2009","unstructured":"Ricci JR, Coulen C, Berger JE, Moore MC, McQueen A, Jan SA. Prescriber compliance with black box warnings in older adult patients. Am J Manag Care 2009;15:e103\u20138.","journal-title":"Am J Manag Care"},{"key":"1633_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/pds.1193","volume":"15","author":"AK Wagner","year":"2006","unstructured":"Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1633_CR10","unstructured":"Generali JA. Drugs with Black Box Warnings\u2014Comprehensive List. Form Web. Available at http:\/\/blackboxrx.com\/. Accessed December 28, 2010."},{"key":"1633_CR11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","volume":"165","author":"DK Wysowski","year":"2005","unstructured":"Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969\u20132002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363\u20139.","journal-title":"Arch Intern Med"},{"key":"1633_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1310\/hpj4301-7","volume":"43","author":"JA Generali","year":"2008","unstructured":"Generali JA. The continuing dilemma of drugs with black box warnings. Hospital Pharmacy 2008;43:7.","journal-title":"Hosp Pharm"},{"key":"1633_CR13","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","volume":"287","author":"KE Lasser","year":"2002","unstructured":"Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215\u201320.","journal-title":"JAMA"},{"key":"1633_CR14","doi-asserted-by":"publisher","first-page":"42S","DOI":"10.1592\/phco.30.pt2.42S","volume":"30","author":"JH Raber","year":"2010","unstructured":"Raber JH. The formulary process from a risk management perspective. Pharmacotherapy 2010;30:42S\u20137S.","journal-title":"Pharmacotherapy"},{"key":"1633_CR15","first-page":"403","volume":"53","author":"JE Beach","year":"1998","unstructured":"Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J 1998;53:403\u201311.","journal-title":"Food Drug Law J"},{"key":"1633_CR16","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1592\/phco.30.pt2.35S","volume":"30","author":"BA Boucher","year":"2010","unstructured":"Boucher BA. Formulary decisions: then and now. Pharmacotherapy 2010;30:35S\u201341S.","journal-title":"Pharmacotherapy"},{"key":"1633_CR17","unstructured":"Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]: U.S. Food and Drug Administration 08 July 2008. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126085.htm. Accessed December 28, 2010."},{"key":"1633_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/archinte.166.3.338","volume":"166","author":"KE Lasser","year":"2006","unstructured":"Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006;166:338\u201344.","journal-title":"Arch Intern Med"},{"key":"1633_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0952-8180(02)00444-0","volume":"14","author":"BA Liang","year":"2002","unstructured":"Liang BA. FDA use of the black box warning: time for reevaluation as a safety tool. J Clin Anesth 2002;14:561\u20133.","journal-title":"J Clin Anesth"},{"key":"1633_CR20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1213\/ane.0b013e31816ba463","volume":"106","author":"AS Habib","year":"2008","unstructured":"Habib AS, Gan TJ. Pro: The Food and Drug Administration Black box warning on droperidol is not justified. Anesth Analg 2008;106:1414\u20137.","journal-title":"Anesth Analg"},{"key":"1633_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","volume":"170","author":"ER Dorsey","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010;170:96\u2013103.","journal-title":"Arch Intern Med"},{"key":"1633_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ACO.0b013e328338c9f7","volume":"23","author":"K Halloran","year":"2010","unstructured":"Halloran K, Barash PG. Inside the black box: current policies and concerns with the United States Food and Drug Administration\u2019s highest drug safety warning system. Curr Opin Anaesthesiol 2010;23:423\u20137.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1633_CR23","unstructured":"Top 200 Drugs for 2008 by Sales. Available at http:\/\/www.drugs.com\/top200.html. Accessed December 28, 2010."},{"key":"1633_CR24","unstructured":"PDR\u00ae Electronic Library\u2122 2009, 63rd ed. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc."},{"key":"1633_CR25","unstructured":"Drugs@FDA- FDA Approved Drug Products. US Food and Drug Administration\/Center for Drug Evaluation and Research. Available at www.accessdata.fda.gov\/Scripts\/cder\/DrugsatFDA. Accessed December 28, 2010."},{"key":"1633_CR26","unstructured":"MedWatch Safety Alerts for Human Medical Products. US Food and Drug Administration. Available at http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/default.htm. Accessed December 28, 2010."},{"key":"1633_CR27","unstructured":"Food and Drug Administration. CDER Reports to the Nation. Available at http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/ucm078859.htm. Accessed December 28, 2010."},{"key":"1633_CR28","unstructured":"Food and Drug Administration. CDER 2000 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2001. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM079006.pdf. Accessed December 28, 2010."},{"key":"1633_CR29","unstructured":"Food and Drug Administration. CDER 2001 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2002. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM078997.pdf. Accessed December 28, 2010."},{"key":"1633_CR30","unstructured":"Food and Drug Administration. CDER 2002 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2003. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM078985.pdf. Accessed December 28, 2010."},{"key":"1633_CR31","unstructured":"Food and Drug Administration. CDER 2003 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2004. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM078975.pdf. Accessed December 28, 2010."},{"key":"1633_CR32","unstructured":"Food and Drug Administration. CDER 2004 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2005. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM078941.pdf. Accessed December 28, 2010."},{"key":"1633_CR33","unstructured":"Food and Drug Administration. CDER 2005 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Maryland, 2005. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM078935.pdf. Accessed December 28, 2010."},{"key":"1633_CR34","unstructured":"Food and Drug Administration. CDER 2007 Update\u2014Improving Public Health Through Human Drugs. Available at http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/WhatWeDo\/UCM121704.pdf. Accessed December 28, 2010."},{"key":"1633_CR35","unstructured":"FDA\u2019s safety information and adverse event reporting program. Available at http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/default.htm. Accessed December 28, 2010"},{"key":"1633_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ajem.2004.09.019","volume":"23","author":"JL Jacoby","year":"2005","unstructured":"Jacoby JL, Fulton J, Cesta M, Heller M. After the black box warning: dramatic changes in ED use of droperidol. Am J Emerg Med 2005;23:196.","journal-title":"Am J Emerg Med"},{"key":"1633_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/DBP.0b013e31817bd7c9","volume":"29","author":"A Cheung","year":"2008","unstructured":"Cheung A, Sacks D, Dewa CS, Pong J, Levitt A. Pediatric prescribing practices and the FDA black-box warning on antidepressants. J Dev Behav Pediatr 2008;29:213\u20135.","journal-title":"J Dev Behav Pediatr"},{"key":"1633_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archpsyc.64.4.466","volume":"64","author":"CB Nemeroff","year":"2007","unstructured":"Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007;64:466\u201372.","journal-title":"Arch Gen Psychiatry"},{"key":"1633_CR39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00004479-200404000-00005","volume":"27","author":"K Redmond","year":"2004","unstructured":"Redmond K. The US and European regulatory systems: a comparison. J Ambul Care Manage 2004;27:105\u201314.","journal-title":"J Ambul Care Manage"},{"key":"1633_CR40","first-page":"501","volume":"162","author":"NS Rawson","year":"2000","unstructured":"Rawson NS. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996\u20131998. CMAJ 2000;162:501\u20134.","journal-title":"CMAJ"},{"key":"1633_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMp0905338","volume":"361","author":"R Platt","year":"2009","unstructured":"Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network\u2014improving the evidence of medical-product safety. N Engl J Med 2009;361:645\u20137.","journal-title":"N Engl J Med"},{"key":"1633_CR42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-144-4-200602210-00013","volume":"144","author":"JP Ioannidis","year":"2006","unstructured":"Ioannidis JP, Mulrow CD, Goodman SN. Adverse events: the more you search, the more you find. Ann Intern Med 2006;144:298\u2013300.","journal-title":"Ann Intern Med"},{"key":"1633_CR43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JP Ioannidis","year":"2004","unstructured":"Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781\u20138.","journal-title":"Ann Intern Med"},{"key":"1633_CR44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn\u2019t. BMJ 1996;312:71\u20132.","journal-title":"BMJ"},{"key":"1633_CR45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","volume":"181","author":"JP Ioannidis","year":"2009","unstructured":"Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009;181:488\u201393.","journal-title":"CMAJ"},{"key":"1633_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2009.973","volume":"302","author":"AB O\u2019Connor","year":"2009","unstructured":"O\u2019Connor AB. The need for improved access to FDA reviews. JAMA 2009;302:191\u20133.","journal-title":"JAMA"},{"key":"1633_CR47","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJMp0907708","volume":"361","author":"LM Schwartz","year":"2009","unstructured":"Schwartz LM, Woloshin S. Lost in transmission\u2014FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717\u201320.","journal-title":"N Engl J Med"},{"key":"1633_CR48","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2165\/11316670-000000000-00000","volume":"32","author":"DM Cook","year":"2009","unstructured":"Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf 2009;32:1057\u201366.","journal-title":"Drug Saf"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-011-1633-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-011-1633-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-011-1633-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-011-1633-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:07:40Z","timestamp":1659089260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-011-1633-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1633"],"URL":"https:\/\/doi.org\/10.1007\/s11606-011-1633-9","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,1]]},"assertion":[{"value":"29 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}